take think hiv trend
rebound
revenu came lower expect legaci hiv
busi impact inventori total product revenu
vs consensu yescarta surpris upsid sale
vs consensu earlier today novarti approv dlbcl
model competit still estim
updat revenu vs prior assumpt market
stock weak probabl base concern around hiv overal
guidanc achiev review hiv trend new
product sale gilead re-affirmed net product sale
weak compar consensu product
estim product sale miss consensu roughli investor
question focus whether guidanc achiev though
reiter adjust revenu estim soft still
believ guidanc achiev total product revenu expect
adjust model break follow hcv
hiv yescarta product
ep
previous reflect sale estim reduct
reflect trough ep year risk neutral rate
target price includ product sale beat greater expect pipelin
success strateg accret upsid guidanc
miss clinic failur safeti event particularli market yescarta
downsid
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
gilead biotechnolog compani focus develop
commerci antivir treatment product includ
sovaldi harvoni hepat stribild complera/eviplera
atripla truvad viread hiv
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
grey sky scenario model car-t platform
success beyond dlbcl filgotanib nash
program fail maintain base case third line yescarta hiv
hcv sale
sky scenario model probabl success
yescarta expans well filgotanib nash maintain
base case third line yescarta hiv hcv sale
 close
hiv inventori impact significantli higher typic hold
somewhat due grow hiv rev like genvoya lower hiv
hbv revenu roughli speak manag think
impact hiv roughli doubl histor season would guess
vs prior drawdown manag remain confid
demand trend underli busi biktarvi light
manag believ right track week launch quarter
note updat hh guidelin like help address prior
author pushback may occur earlier day
yescarta track in-lin compani expect cours beat
expect post sale manag view launch earli
thing go well measur launch believ sinc dynam
launch differ mani biotech still remain earli give
sort revenu guidanc detail trend time pass
still give gilead signific flexibl grow top-lin revenu
near-term gilead roughli cash balanc sheet deal
still believ compani remain activ compani remain interest
accret deal deal larger kite cours
ambit remain challeng current landscap
compani mention price
